Cell therapy startup NKILT Therapeutics takes novel approach to targeting leukemia

Founded in the summer of 2021, biotech startup NKILT Therapeutics is developing a novel approach of engineering natural killer (NK) cells to directly target leukemias first, and later solid tumors.

Science Advisory Board spoke with Raphaël Ognar, co-founder and CEO of NKILT Therapeutics, earlier this month at the 2022 Cell & Gene Meeting on the Mesa in Carlsbad, CA.

Ognar described the company's platform which takes an allogeneic approach using armored NK cells that not only directly kill cancer cells but are designed to activate innate immunity and directly target the tumor's defense mechanisms.

"We have now this foundation data that we can build upon to move to the next phase that is going to be expanding the proof of concept," said Ognar. "Once we have done this, we should be ready by the second half of next year to go for a larger fundraising round."

Watch this video to learn more.

Antion Biosciences takes allogeneic approach to therapies with microRNA technology
Science Advisory Board spoke with Dr. Sven Kili, CEO of Antion Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa, where he laid...
NKILT moves from stealth mode to active fundraising
ScienceBoard.net recently caught up with NKILT Therapeutics leaders Raphael Ognar and Henri Bayle at the 2022 American Association for Cancer...
Why one industry veteran launched a new cancer immunotherapy company
WASHINGTON, DC - Raphaël Ognar spoke with ScienceBoard onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting about the launch...

Copyright © 2022 scienceboard.net

Last Updated 10/25/2022 1:23:28 PM